And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

CATX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 5.72%

Insider Buying (Last 12 Months): 57,664,972.30

Insider Selling (Last 12 Months): 0.00

Perspective Therapeutics Insider Trading History Chart

Perspective Therapeutics Share Price & Price History

1.58

▼ -0.02 (-1.25%)

As of 04/26/2024 09:52 PM ET

Days: 30 | 90 | 365

He Is Giving Away Bitcoin

From Crypto Swap Profits | Ad

>> Register right here

Perspective Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/6/2024	Lantheus Alpha Therapy, Llc	Major Shareholder	Buy	60,431,039	0.95	57,409,487.05	116,773,394
1/29/2024	Robert F Williamson III	Director	Buy	25,266	0.64	16,170.24	211,555
1/25/2024	Robert F Williamson III	Director	Buy	22,134	0.49	10,845.66	75,676
1/24/2024	Markus Puhlmann	Insider	Buy	280,000	0.50	140,000.00	1,375,425
12/21/2023	Robert F Williamson III	Director	Buy	3,663	0.33	1,208.79	3,663
12/18/2023	Jonathan Robert Hunt	CFO	Buy	125,000	0.26	32,500.00	316,710
12/18/2023	Markus Puhlmann	Insider	Buy	60,419	0.26	15,708.94	695,425
12/18/2023	Robert F Williamson III	Director	Buy	10,000	0.26	2,600.00	10,000
12/15/2023	Markus Puhlmann	Insider	Buy	135,006	0.27	36,451.62	635,006

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

From Banyan Hill Publishing | Ad

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Watch my video for all of the details

SEC Filings (Institutional Ownership Changes) for Perspective Therapeutics (NYSEAMERICAN:CATX)

54.66% of Perspective Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Perspective Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/26/2024	ZWJ Investment Counsel Inc.	22,000	$26K	0.0%	N/A	0.004%
4/24/2024	Simplicity Wealth LLC	33,570	$40K	0.0%	N/A	0.006%
1/22/2024	Perkins Capital Management Inc.	700,000	$0.28M	0.2%	-73.8%	0.249%
1/11/2024	Taylor & Morgan Wealth Management LLC	625,000	$0.25M	0.2%	+8.7%	0.223%
11/8/2023	HighTower Advisors LLC	1,147,038	$0.31M	0.0%	N/A	0.409%
11/2/2023	Perkins Capital Management Inc.	2,671,644	$0.73M	0.7%	N/A	0.952%
10/24/2023	Bank of New York Mellon Corp	154,238	$42K	0.0%	N/A	0.055%
10/16/2023	Wealth Effects LLC	110,000	$30K	0.0%	N/A	0.039%
10/5/2023	Taylor & Morgan Wealth Management LLC	575,000	$0.16M	0.1%	N/A	0.205%

Data available starting January 2016

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Today's Range

Now: 1.58

1.53

1.62

50 Day Range

MA: N/A

52 Week Range

Now: 1.58

0.21

1.77

Volume

4,686,100 shs

Average Volume

6,322,404 shs

Market Capitalization

$927.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56

Who are the company insiders with the largest holdings of Perspective Therapeutics?: Perspective Therapeutics' top insider investors include:
Lantheus Alpha Therapy, Llc (Major Shareholder)
Markus Puhlmann (Insider)
Jonathan Robert Hunt (CFO)
Robert F Williamson III (Director)
Learn More about top insider investors at Perspective Therapeutics.
Who are the major institutional investors of Perspective Therapeutics?: Perspective Therapeutics' top institutional shareholders include:
Simplicity Wealth LLC — 0.01%
ZWJ Investment Counsel Inc. — 0.00%
Learn More about top institutional investors of Perspective Therapeutics stock.
Which major investors are buying Perspective Therapeutics stock?: In the last quarter, CATX stock was acquired by institutional investors including:
Simplicity Wealth LLC
ZWJ Investment Counsel Inc.
During the previous year, these company insiders have bought Perspective Therapeutics stock:
Lantheus Alpha Therapy, Llc (Major Shareholder)
Markus Puhlmann (Insider)
Jonathan Robert Hunt (CFO)
Robert F Williamson III (Director)
Learn More investors buying Perspective Therapeutics stock.